Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review

Clinical Oncology

Volumn 24, Issue 6, 2012, Pages 410-412

  Larkin, J M G ^a   Fisher, R A ^a   Gore, M E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON;

ANOREXIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EDITORIAL; FATIGUE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MELANOMA; MOOD DISORDER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME;

HUMANS; INTERFERONS; MELANOMA; SKIN NEOPLASMS;

EID: 84863825197     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.03.010     Document Type: Editorial

References (25)

1. Petrella T., Verma S., Spithoff K., et al. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review. Clin Oncol 2012, 24(6):413-423.
2. Fisher R., Cahalin P., Gore M., et al. A tale of two tumours and a plea for progress. Lancet Oncol 2012, 13(2):124-125.
3. Eggermont A.M., Suciu S., Ruka W., et al. EORTC 18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. J Clin Oncol 2008, 26(Suppl.). abstract 9004.
4. Eggermont A.M., Suciu S., Santinami M., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372(9633):117-126.
5. McMasters K.M., Ross M.I., Reintgen D.S., et al. Final results of the Sunbelt Melanoma Trial. J Clin Oncol 2008, 26(Suppl.). abstract 9003.
6. Pectasides D., Dafni U., Bafaloukos D., et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009, 27(6):939-944.
7. Eggermont A.M., Suciu S., MacKie R., et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005, 366(9492):1189-1196.
8. Stadler R., Luger T., Bieber T., et al. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: a controlled, randomised multicentre trial. Acta Oncol 2006, 45(4):389-399.
9. Garbe C., Radny P., Linse R., et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008, 19(6):1195-1201.
10. Hauschild A., Weichenthal M., Rass K., et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 2010, 28(5):841-846.
11. Wheatley K., Ives N., Eggermont A.M., et al. Interferon-a as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol 2007, 25(18s). abstract 8526.
12. Mocellin S., Pasquali S., Ross C.R., et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102(7):493-501.
13. Dixon S., Walters S.J., Turner L., et al. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006, 94(4):492-498.
14. Bottomley A., Coens C., Suciu S., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009, 27(18):2916-2923.
15. Sargent D.J., Patiyil S., Yothers G., et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007, 25(29):4569-4574.
16. de Gramont A., Hubbard J., Shi Q., et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 2009, 28(3):460-465.
17. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954.
18. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353(20):2135-2147.
19. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24(26):4340-4346.
20. Van Raamsdonk C.D., Griewank K.G., Crosby M.B., et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 363(23):2191-2199.
21. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516.
22. Carvajal R.D., Antonescu C.R., Wolchok J.D., et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011, 305(22):2327-2334.
23. Guo J., Si L., Kong Y., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011, 29(21):2904-2909.
24. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
25. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-2526.